Showing results (61-70 of 88) with videos related to
Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapyPaul A Foster, Simon P Newman, Surinder K Chander, et al.Breast Cancer Research and Treatment|October 5, 2007
Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancerPaul A Foster, Surinder K Chander, Michael F C Parsons, et al.Organic & Biomolecular Chemistry|October 31, 2008
Effects of C-17 heterocyclic substituents on the anticancer activity of 2-ethylestra-1,3,5(10)-triene-3-O-sulfamates: synthesis, in vitro evaluation and computational modellingFabrice Jourdan, Christian Bubert, Mathew P Leese, et al.Biochemistry|May 4, 2005
First crystal structures of human carbonic anhydrase II in complex with dual aromatase-steroid sulfatase inhibitorsMatthew D Lloyd, Nethaji Thiyagarajan, Yaik T Ho, et al.Bioorganic & Medicinal Chemistry|March 11, 2008
Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for designGillian M Allan, Nigel Vicker, Harshani R Lawrence, et al.Journal of Medicinal Chemistry|February 13, 2010
Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl templateL W Lawrence Woo, Toby Jackson, Aurélien Putey, et al.Chemmedchem|July 16, 2010
Bicyclic derivatives of the potent dual aromatase-steroid sulfatase inhibitor 2-bromo-4-{[(4-cyanophenyl)(4h-1,2,4-triazol-4-yl)amino]methyl}phenylsulfamate: synthesis, SAR, crystal structure, and in vitro and in vivo activitiesPaul M Wood, L W Lawrence Woo, Jean-Robert Labrosse, et al.Cancer Research|January 7, 2006
The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cellsSimon P Newman, Christopher R Ireson, Helena J Tutill, et al.Endocrine-Related Cancer|November 8, 2012
STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer modelJoanna M Day, Paul A Foster, Helena J Tutill, et al.Advanced Healthcare Materials|March 12, 2023
The Effect of Cryoprotectants and Storage Conditions on the Transfection Efficiency, Stability, and Safety of Lipid-Based Nanoparticles for mRNA and DNA DeliveryKonstantinos N Kafetzis, Natalia Papalamprou, Elisha McNulty, et al.Pageof 9